{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:27:20Z","timestamp":1787772440590,"version":"build-2784847793"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>To study functional changes in vision and morphological changes on optical coherence tomography (OCT) scans in patients where intravitreal therapy (IVT) with injections has been delayed due to COVID-19 pandemic lockdown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Retrospective cross-sectional study included 77 eyes with the diagnosis of exudative age-related macular degeneration (eAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), regularly receiving IVT with anti-vascular endothelial growth factor (Anti-VEGF) injections or dexamethasone implant and were not able to receive the injections as intended due to lockdown. Best-corrected visual acuity (BCVA), central foveal thickness (CFT), and qualitative morphological features on OCT were analyzed pre- and post-therapy break off.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      The mean duration of IVT break-off was 57 days. Mean BCVA logarithm of minimum angle of resolution (logMAR) worsened from 0.33 (20\/42) to 0.35 (40\/44) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02) and mean CFT increased from 297.90 \u03bcm to 402.16 \u03bcm (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01), from pretherapy break-off to return visit. Worsening of the visual acuity was seen across all the three disease cohorts, significantly more in the eyes with eAMD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Marginal decline in the visual acuity and worsening of the OCT features were observed as a result of delay in the IVT injections of DME, eAMD and RVO patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ojo.ojo_74_21","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T13:51:33Z","timestamp":1716558693000},"page":"168-174","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Impact of COVID-19-related lockdown on retinal disorders treated with intravitreal injections"],"prefix":"10.4103","volume":"15","author":[{"given":"Manpreet","family":"Brar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satinder Pal Singh","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilraj S","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mangat Ram","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20240908","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R2-10-20240908","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"R3-10-20240908","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-10-20240908","first-page":"1562","article-title":"The RIDE and RISE studies of the Efficacy and Safety of Intravitreal Ranibizumab (LUCENTIS\u00ae) in Clinically Significant Macular Edema With Center involvement secondary to diabetes mellitus","volume":"49","author":"Shah","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-10-20240908","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: Six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"R6-10-20240908","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R7-10-20240908","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ophtha.2014.04.024","article-title":"Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema","volume":"121","author":"Boyer","year":"2014","journal-title":"Ophthalmology"},{"key":"R8-10-20240908","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year Outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related Macular degeneration: The comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"key":"R9-10-20240908","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1016\/j.ophtha.2013.03.046","article-title":"Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: A multicenter cohort study (SEVEN-UP)","volume":"120","author":"Rofagha","year":"2013","journal-title":"Ophthalmology"},{"key":"R10-10-20240908","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1097\/IAE.0000000000001494","article-title":"Natural course of patients discontinuing treatment for age-related macular degeneration and factors associated with visual prognosis","volume":"37","author":"Kim","year":"2017","journal-title":"Retina"},{"key":"R11-10-20240908","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/02713683.2018.1543708","article-title":"Adherence to intravitreal anti-Vascular endothelial growth factor (Anti-VEGF) drugs in diabetic macular edema in an Egyptian population: A health belief model","volume":"44","author":"Habib","year":"2019","journal-title":"Curr Eye Res"},{"key":"R12-10-20240908","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4274\/tjo.28003","article-title":"Factors affecting compliance to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration","volume":"47","author":"Polat","year":"2017","journal-title":"Turk J Ophthalmol"},{"key":"R13-10-20240908","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/OPTH.S248661","article-title":"Factors affecting compliance to anti-vascular endothelial growth factor treatment of diabetic macular edema in a cohort of Jordanian patients","volume":"14","author":"Abu-Yaghi","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R14-10-20240908","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s13300-018-0513-2","article-title":"Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: Two-year real-life data from a non-interventional, multicenter study in Germany","volume":"9","author":"Ziemssen","year":"2018","journal-title":"Diabetes Ther"},{"key":"R15-10-20240908","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R16-10-20240908","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2013.12.018","article-title":"Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration","volume":"157","author":"Holekamp","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R17-10-20240908","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.oret.2018.11.002","article-title":"Loss to follow-up after intravitreal anti-vascular endothelial growth factor injections in patients with diabetic macular edema","volume":"3","author":"Gao","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R18-10-20240908","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3928\/23258160-20190301-05","article-title":"Loss to follow-up in patients with retinal vein occlusion undergoing intravitreal anti-VEGF injections","volume":"50","author":"Gao","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R19-10-20240908","first-page":"4878","article-title":"Visual outcomes in eyes lost to follow up with diabetic macular edema treated with anti-vascular endothelial growth factor","volume":"61","author":"Matsunaga","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-10-20240908","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2019.07.010","article-title":"Outcomes of eyes lost to follow-up with neovascular age-related macular degeneration receiving intravitreal anti-vascular endothelial growth factor","volume":"4","author":"Soares","year":"2020","journal-title":"Ophthalmol Retina"},{"key":"R21-10-20240908","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","volume":"10","author":"Virgili","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-10-20240908","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: Ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"R23-10-20240908","first-page":"CD011346","article-title":"Aflibercept for neovascular age-related macular degeneration","volume":"2","author":"Sarwar","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_74_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:46:41Z","timestamp":1787770001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_74_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_74_21","relation":{},"ISSN":["0974-620X"],"issn-type":[{"value":"0974-620X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}